We are live on ! Find out more

1,103 hedge funds and large institutions have $45B invested in Biogen in 2019 Q4 according to their latest regulatory filings, with 204 funds opening new positions, 271 increasing their positions, 471 reducing their positions, and 70 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more first-time investments, than exits

New positions opened: 204 | Existing positions closed: 70

82% more funds holding in top 10

Funds holding in top 10: 1731 (+14)

21% more capital invested

Capital invested by funds: $37.3B → $45B (+$7.76B)

12% more funds holding

Funds holding: 9891,103 (+114)

2.65% less ownership

Funds ownership: 86.84%84.19% (-2.7%)

30% less call options, than puts

Call options by funds: $1.27B | Put options by funds: $1.82B

42% less repeat investments, than reductions

Existing positions increased: 271 | Existing positions reduced: 471

Holders
1,103
Holders Change
+114
Holders Change %
+11.53%
% of All Funds
21.66%
Holding in Top 10
31
Holding in Top 10 Change
+14
Holding in Top 10 Change %
+82.35%
% of All Funds
0.61%
New
204
Increased
271
Reduced
471
Closed
70
Calls
$1.27B
Puts
$1.82B
Net Calls
-$553M
Net Calls Change
-$242M

BIIB Hedge Fund Activity: Q4 2019 in Review

1,103 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2019, worth a combined $45B — up 21% from $37.3B a quarter earlier.

Buyers outnumbered sellers: 204 funds opened new BIIB positions and 70 closed out — a net gain of 134 holders — while 271 added to existing stakes and 471 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $273M. The largest seller was Invesco, cutting an estimated $492M.

  • 1,103 institutional investors held Biogen (BIIB) as of Q4 2019, up from 989 in Q3 2019.
  • Funds reported $45B of Biogen stock for Q4 2019, up 21% quarter-over-quarter.
  • 204 funds opened new Biogen positions in Q4 2019 and 70 closed out, a net change of +134 holders.
  • The largest Biogen buyer in Q4 2019 was Wellington Management Group, an estimated $273M added.
  • The largest Biogen seller in Q4 2019 was Invesco, an estimated $492M sold.

Based on aggregated 13F filings for Q4 2019.